Commercial challenges in developing biomaterials for medical device development
- 17 May 2018
- journal article
- research article
- Published by Wiley in Polymer International
- Vol. 67 (8) , 969-974
Abstract
From initial conceptualization through to market adoption, the introduction of new technology into a commercial market is often fraught with challenges. In the field of biomaterials these challenges manifest themselves at every step of the commercialization process. As the understanding of the mechanobiologic relationship in tissue engineering has progressed, there is greater emphasis being placed on the engineering of specific properties into new biomaterials. During this early development, intellectual property is a critical factor in determining commercial feasibility as patent protection establishes the property lines around the technology and helps define future market segments. Once developed, a new biomaterial then enters the next series of challenges including commercial‐scale manufacturing and addressing regulatory concerns. Synthesis of the biomaterial must be economically and technically scalable to meet market demands and the new biomaterial must be designed to stand up to regulatory scrutiny with regards to safety and efficacy. However daunting, a robust understanding of the design elements and the commercial requirements will aid the researcher in overcoming the challenges of bringing a new biomaterial to the market. © 2018 Society of Chemical IndustryKeywords
This publication has 28 references indexed in Scilit:
- The Biomaterials Conundrum in Tissue EngineeringTissue Engineering Part A, 2014
- Biomimetic poly(glycerol sebacate) (PGS) membranes for cardiac patch applicationMaterials Science and Engineering: C, 2013
- Elastomeric biomaterials for tissue engineeringProgress in Polymer Science, 2013
- Fast-degrading elastomer enables rapid remodeling of a cell-free synthetic graft into a neoarteryNature Medicine, 2012
- Breakthrough: Arthur Blakemore and Arthur Voorhees, JrJournal of Vascular Surgery, 2012
- Substantial expression of mature elastin in arterial constructsProceedings of the National Academy of Sciences, 2011
- Physiologic compliance in engineered small-diameter arterial constructs based on an elastomeric substrateBiomaterials, 2010
- Pre‐treatment of synthetic elastomeric scaffolds by cardiac fibroblasts improves engineered heart tissueJournal of Biomedical Materials Research Part A, 2007
- Biodegradable polymers as biomaterialsProgress in Polymer Science, 2007
- Effect of compliance mismatch on vascular graft patencyJournal of Vascular Surgery, 1987